Dr. Jonathan M. Weiss, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Michigan State University College of Human Medicine (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 35
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: Michigan State University College of Human Medicine
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301511297 -
Hematology (Internal Medicine) Physician
MI license 4301511297
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 35
- Services billed
- 127
- Patients’ average age
- 69
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Ann Arbor, MI | 19 |
| Dexamethasone Other prescribers in Ann Arbor, MI | 13 |
| Prednisone Other prescribers in Ann Arbor, MI | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $134 in total to this clinician.
| Genmab U.S., Inc. | $109 |
|---|---|
| Incyte Corporation | $25.00 |
| Food and Beverage | $134 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $162,057 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously …
Celgene Corporation - Phase I multi-site study evaluating the MTD, safety and efficacy of the combination venetoclax, lenalidomide and rituximab in patients with previously untreated mantle cell lymphoma
AbbVie Inc. - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.